GT Biopharma is trading 6.19% down at $5.61 after a sharp post-reverse-split rally.
- The 1-for-25 reverse stock split became effective September 8, reducing shares outstanding and changing its CUSIP.
- Nasdaq and market coverage confirm the corporate action; no new September 10 announcement, earnings release, or other clear catalyst explains the pre-market decline.